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ASSESSING THE IMMUNIGENICITY OF THE MAJOR OUTER MEMBRANE 
PROTEIN PORIN B OF NESSERIA GONORRHOEAE AS A VACCINE 
CANDIDATE 
TUQUYNH LE 
ABSTRACT 
 Neisseria gonorrhoeae is a strict human pathogen and the causative agent of the 
sexually transmitted disease, gonorrhea. Gonococcal (GC) diseases remain one of the 
most reported sexually transmitted infections (STI) worldwide, representing a significant 
threat to reproductive health and burden on global health systems, accounting for 541,987 
disability adjusted-life years in the year 2011. Infection by N. gonorrhoeae also increases 
the likelihood of patient acquisition and transmission of human immunodeficiency virus 
(HIV). Unfortunately, antibiotic treatment to gonococcal diseases is being threatened by 
the rapid spread of resistance to third-generation cephalosporins, the remaining treatment 
option used in clinics. The urgency of the situation is compounded by the relative lack of 
immunological protection conferred by previous infection by the bacterium. In response 
to the emergence of multidrug resistance, renewed energies are being directed towards 
the development of an effective, broadly protective vaccine.  Difficulties in vaccine 
development arise from a lack of known correlates of protective immunity; there is no 
known broadly cross-protective immunity to GC and a truly reflective animal model has 
not been available. Nonetheless, previous studies have indicated that porins, neisserial 
major outer membrane proteins, are promising vaccine candidates. PorB makes up over 
60% of the bacterium’s outer membrane content and is involved in solute and ion 
  vii
exchange, invasion of target host cells, and evasion of host immunity. Porins from both 
the gonococcus and the meningococcus have been shown to have immunostimulatory 
activity, boosting B and dendritic (DC) cell proliferation and maturation in the absence of 
an exogenous adjuvant as mediated by TLR2 and MyD88.  Importantly, as a potential 
vaccine candidate, PorB has relatively low antigenic variability, and can induce 
bactericidal antibodies. Gonococcal PorB was purified from a genetically modified strain, 
MS11∆P3, which lacks another outer membrane protein, RMP, which is known to induce 
bactericidal blocking antibodies. PorB was formed into pure protein micelles, termed 
proteosomes, to protect the integrity of the native trimeric structure. Our study 
demonstrated that gonococcal PorB is able to stimulate both human embryonic kidney 
(HEK) cell line that overexpresses TLR2 and mouse primary macrophages (similar to the 
meningococcal PorB). To test PorB’s immunogenicity, mice were immunized three times 
at two week intervals with PorB and porin specific IgG levels were measured. 
Unfortunately, PorB elicited lower levels of porin specific IgG than what was expected, 
which may be due to technical issues. We are currently investigating various possibilities. 
In addition, further immunization studies shall be carried out to better contextualize these 
results.   
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INTRODUCTION  
 
Epidemiology 
 
Neisseria gonorrhoeae, a gram negative diplococcus, is a strict human pathogen 
and the causative agent of the sexually transmitted disease, gonorrhea. An ancient 
disease, gonorrhea remains one of the major reported infections in the world with over 
106 million new cases a year(“WHO | Global action plan to control the spread and impact 
of antimicrobial resistance in Neisseria gonorrhoeae,” n.d.). In the US alone, 330,000 
new cases were diagnosed in 2012 however, due to underreporting, the CDC estimates 
the true number to be approximately 820,000 (“2012 STD Surveillance Gonorrhea | 
CDC,” n.d.). In the year 2011, it was estimated that 541,987 disability adjusted-life years 
(DALYs) were attributable to gonococcal (GC) infections (“WHO | Regional estimates 
for 2000-2011,” n.d.)  
Gonococcal diseases range in severity, with presentation differing between the 
sexes, and can significantly impact reproductive health. Both men and women may 
experience symptomatic urethritis, extra-genital rectal and pharyngeal infections, and, in 
rare cases disseminated gonococcal infections (0.5-3%)(Jerse et al., 2014). In cases of 
disseminated infections, patients can develop arthritis-dermatitis syndrome, suppurative 
arthritis, endocarditis, and meningitis.  
In men, untreated urethritis cases can lead to epididymitis and infertility 
(Campbell, 1928). In women, GC can result in asymptomatic mucosal infection, 
cervicitis, endometritis, upper genital tract infections, and eventually progress to pelvic 
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inflammatory disease (PID). If untreated, PID can lead to ectopic pregnancies, tubal 
infertility, and chronic pain (“2012 STD Surveillance Gonorrhea | CDC,” n.d.). PID is 
estimated to affect 1 in 10 women, 40% of the cases are attributable to Neisseria 
gonorrhoeae as the underlying agent (Sweet et al., 1986). Infertility rates associated with 
PID are high, affecting >10% of patients after the first episode and increasing 
precipitously to >50% following 3 or more episodes (Weström, 1994). Active GC 
infections during pregnancy can cause chorioamnionitis, septic abortion, or pre-term 
delivery. During delivery, infected mothers can transmit the disease to their newborn. 
Infected neonates may develop conjunctival infections, leading to scarring of the cornea 
and blindness, skin infections, or disseminated disease (Woods, 2005). Apart from the 
direct effects of gonoccocal diseases, GC also leads to increased risk of acquisition and 
transmission of type 1 human immunodeficiency virus (HIV) via the induction of acute 
inflammation, leading to loss of mucosal integrity, and increased HIV viral RNA 
expression (Zhang et al., 2005).  
Gonococcal infections represent a large burden on global health, yet current 
systems of detection and treatment are insufficient to meet the challenge. The current 
standard for diagnosing GC infection is by bacterial culture from a swab taken of the 
infected area. However, this test is less effective at detection of GC in asymptomatic 
infections. Efforts have been made to develop sensitive rapid DNA testing, but the cost 
and resources required for these methods lead to clinical management based on 
symptomatic presentation in most resource-limited settings. As a result, the disease 
disproportionately burdens socially or economically disadvantaged populations.  
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Treatment options for gonococcal diseases have dwindled with the rising 
incidence of antibiotic resistant strains. Over the last decade, N. gonorrhoeae has 
developed resistance to both penicillin and quinolones, leaving cephalosporins as the 
remaining treatment option. Alarmingly, high-level resistance to ceftriaxone, a third-level 
cephalosporin, emerged in Japan in 2011 and increased resistance is reported in other 
East Asian countries, as well as the US (Ohnishi et al., 2011). In light of the increasingly 
real threat of untreatable gonococcal infections, it becomes imperative to work towards 
the development of preventive measures, such as vaccines.  
 
Brief Overview: Gonococcal Major Outer Membrane Components 
 
Neisseria gonorrhoeae lacks a polysaccharide capsule, exposing its outer 
membrane components to the environmental milieu. Many of these components mediate 
interactions with its host. Neisserial porins exist as a trimer consisting of three 16-strand 
β-barrel folds that acts as a pore for solute and ion transport. The porin makes up roughly 
60% of the outer membrane components and has low antigenic variability. In the 
gonococcus, there are two subtypes of porin, protein 1A (P1A) and protein 1B 
(P1B)(Wetzler, 2010). PorB is closely associated with the reduction modifiable protein 
(RMP, protein III) which is constitutively expressed and lacks antigenic variability 
(Plummer et al., 1993). Protein II or Opacity protein (Opa) functions as adhesions in GC 
to GC and GC to host cell interactions. The outer membrane also contain Pili, 
multifunctional appendages integral to distant attachment of GC to eukaryotic cells, 
genetic exchange, bacterial aggregation, and twitching motility(Cahoon & Seifert, 2011) 
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Opa and Pili undergo significant phase variation. The outer membrane also contains 
lipooligosaccharide (LOS), a low molecular weight variation of lipopolysaccharide (LPS) 
that lacks O-antigen (Kilár et al., 2013). Other outer membrane proteins are differentially 
expressed based on environment cues, such as environmental iron or oxygen levels.  
 
Disease Pathogenesis 
 
Understanding the pathogen’s routes of infection is fundamental to tailoring an 
effective vaccine against it. Adhesion is mediated by either attachment of GC type IV pili 
(Cahoon & Seifert, 2011) or the interaction of GC Opa protein with human CEACAM 
glycoproteins allowing intimate attachment of the bacterium to mucosal epithelia and 
prevents epithelial sloughing. The Gray-Owen laboratory has recently discovered that 
carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1)-specific Opa 
variants are required for ascending infections, as one would see in PID. CEACAM5-
specific Opa variants are sufficient for cervico-vaginal colonization (unpublished data). 
The adherence of GC allows transcytosis of the bacterium into sub-epithelial spaces and 
suppresses innate and adaptive immune responses (Virji et al., 1996). In women, cervical 
cells uptake the bacterium through the complement 3 receptor (CR3) which recognizes a 
complex of gonococcal LOS, gonococcal porin (PorB), and inactivated host complement 
iC3b (Edwards & Apicella, 2004). In male urethral cells, bacterial lacto-N-neotretraose 
(LNT), a type LOS, binds to the host asialoglycoprotein receptor for uptake.  
Following invasion, GC is effectively evades host innate immunity. The 
bacterium is able to expel hydrophobic anti-microbial substances, such as bile salts, fatty 
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acids, progesterone, and anti-microbial peptides, through its MtE-MtC-MtE pump system 
(Shafer et al., 2001). Furthermore, GC accesses host iron supplies by expressing receptors 
for human transferrin (Tf) and lactoferrin, bypassing host iron sequestration attempts 
(Schryvers & Stojiljkovic, 1999). Through sialylation of LNT, the bacterium increases its 
resistance to complement mediated defenses and decreases its vulnerability to 
phagocytosis by polymorphonuclear leukocytes (PMN). Complement is also evaded by 
up-regulation of the porin expression, which binds C4b binding protein and factor H 
(Massari et al., 2003). PorB may also prevent release of reactive-oxygen species (ROS) 
from PMNs into the extracellular milieu (Lorenzen et al.,2000).  
 
Host Response 
 
In men, infection by GC induces an inflammatory response including pro-
inflammatory cytokines and chemokines, resulting in a purulent exudate consisting of 
PMNs, shed epithelial cells, and intracellular and extracellular GC (Ramsey et al., 1994). 
In women, infection often does not present symptoms unless the patient has been co-
infected by another STI (Edwards & Apicella, 2004). Experiments in the mouse model 
indicate GC induces Th17 cells, in part through LOS signaling through toll-like receptor 
4 (TLR4) and LOS interactions with lectins, resulting in a high inflammatory response 
(Feinen et al., 2010). PorB and factor H up-regulate inflammation through stimulation of 
TLR2 which leads to NF-κB activation and dendritic cell (DC) maturation. GC also 
activates the nucleotide-binding, leucine-rich protein 3 (NLRP3) inflammasome pathway 
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in mature DCs resulting in production of inflammatory cytokines interleukin-1β (IL-1β) 
and interleukin-18 (IL-18) and cellular pyronecrosis (Singleton et al., 2005).  
 Despite a robust inflammatory innate immune response, the adaptive immune 
response to Neisseria gonorrhoeae is weak, as evidenced by the prevalence of recurrent 
infections. In uncomplicated infections of urethritis or cervicitis there is a limited 
antibody response to homologous clinical isolates that is not sustained in follow-up (Jerse 
et al,. 2013). Binding of GC Opa proteins to CEACAM1 down regulate CD-4+ T cell 
proliferation, hampering T cell, B cell interaction (Boulton &Gray-Owen, 2002). In the 
absence of this interaction, production of T-cell dependent memory response is inhibited. 
Instead, infection by GC preferentially induces a low specificity poly-clonal IgM+ B cell 
response by expansion of IgD+CD27+ B cells, precluding induction of classical adaptive 
immune responses (So, Ostrowski & Gray-Owen, 2012). Infection also gives rise to 
mucosal and parenteral IgA and IgG antibodies to GC major outer membrane proteins, 
Opa, RMP, Pili, LOS, and PorB (Brooks & Lammel, 1989). There is some debate as to 
whether or not GC actively suppresses the Th1 and Th2 response as well by induction of 
type 1 regulatory T cells (Gagliardi et al., 2011) and through IL-10 and TGF-β dependent 
mechanisms (Liu et al., 2012). The gonococcus also expresses blocking antigens and 
immunoglobulin (Ig) A1 protease, has high variability in expressed surface antigens, and 
can retreat into epithelial cells and induce membrane blebbing to create decoys in order to 
evade antibody response (Jerse, Bash, & Russell, 2013).  
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Vaccine Development 
 
The recurrence of GC infections without significant induction of protective 
immunological memory does not preclude the potential to do so, but rather that broad 
protection does not develop within the contexts of infection. To wit, a longitudinal study 
of Kenyan sex workers conducted by Plummer et al. indicates strains of a different 
serotype than the initial infecting strain are more likely to cause reinfection (Plummer et 
al., 1989). These results suggest the development of serotype specific immunity.  
 Efforts towards development of an effective gonococcal vaccine have been 
ongoing for over 30 years but progress has been hindered by a lack of known immune 
correlates of protection. As immunity conferred by infection seems to be, at best, serovar 
specific, determination of factors that would confer broad protection is difficult. Further, 
correlation of incidence with development of immunity is unclear as a large proportion of 
infected individuals are asymptomatic. Most significantly, the exquisite mechanisms GC 
has evolved to best exploit its human host has left researchers without a representative 
animal model. In order to study disease progression in a small scale model, a 17-β 
estradiol mouse model has been developed by the Jerse lab (Jerse et al., 2011). Although 
the addition of the estrogen allows for a sustained GC infection, the underlying 
mechanism is unknown. Furthermore, this mouse model lacks Pili and Opa binding 
receptors, iron binding proteins appropriate for GC growth, and expression of human C4 
binding protein (C4bp) or factor H. These deficiencies, in combination, make the 
translation of results from mouse to human a precarious proposition. Compounding these 
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issues is a relative lack of detailed knowledge of the clearly distinct mucosal immune 
microenvironment found in the genitourinary tract as compared to the rest of the body. 
 To surmount the deficiencies in the estrous mouse model, the Gray-Owen lab has 
been working towards a humanized transgenic mouse to better reflect infection 
progression in humans. Furthermore, the production of IgG, IgA and IgM against of the 
gonococcal major outer membrane proteins is promising. PorB is of particular interest as 
a vaccine candidate to our lab. Past studies have shown that PorB can induce an immune 
response in the absence of an additional adjuvant. (Lee M Wetzler, 2010). PorB adjuvant 
activity is mediated by protein binding to toll-like receptor 2 (TLR2) and subsequent 
signaling through the myeloid differentiation primary response gene 88(MyD88) 
resulting in nuclear translocation of NF-κB.  This signaling cascade increases expression 
of the major histocompatibility complex (MHC) class II and CD86, induction of B cell 
proliferation, and dendritic cell maturation (Singleton et al., 2005). As an antigen, PorB is 
of interest due to its aforementioned low variability and represents a majority of the outer 
membrane components. Analysis of anti-PorB antibodies shows opsonic and bactericidal 
activity (L M Wetzler et al., 1992).  
 Previously, a PorB vaccine trial was performed in Seattle with disappointing 
results. The collected sera had minimal bactericidal activity and low quantities of anti-
PorB antibodies(Tramont, 1989). However, recent analysis of these sera indicates high 
levels of anti-RMP immunoglobulin G (IgG). Subsequent to this vaccine trial, Plummer 
et al. found that anti-RMP antibody increases vulnerability to gonococcal infections by 
blocking complement dependent bactericidal activity of other antibodies (Plummer et al., 
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1993). As RMP is highly immunogenic itself, its presence in a vaccine preparation would 
skew antibody production towards anti-RMP and result in fewer, effective anti-PorB 
antibodies. In addition, it is believed that the PorB preparation used in this vaccination 
study may have contained non-trimeric and mis-folded porin reducing antibody 
recognition and efficacy, a failing our lab has been able to overcome through improved 
purification protocols (Massari et al., 2005).  Proteosomes made from a clean PorB 
preparation and immunized in rabbits at 100µg per rabbit were able to produce high 
serum anti-PorB antibody (L M Wetzler et al., 1992). 
 In the context of these recent improvements, a renewed effort was made to 
characterize the immunogenic properties of PorB. In this study, PorB was isolated from 
MS11∆P3, a modified strain that lacks RMP. The stimulatory activity of the purified 
porin was observed in both human epithelial and murine macrophage cells. Upon 
observation of stimulation, a mouse immunization study was carried out and porin-
specific IgG was measured.  
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METHODS 
 
Materials and Reagents  
 
Neisseria Gonorrhoeae Growth Media 
 
Gonococcal Agar Base was purchased from Remel (#R453502). 36 grams of 
mixture was reconstituted in 500mL of dH2O and autoclaved. Autoclaved agar solution 
was then cooled to 50°C in water bath and supplemented to 1% (v/v) BD BBL™ 
IsoVitalX Enrichment (#211876). The solution was poured into 90x15mm petri dishes 
and allowed to solidify. Prepared plates were stored at 4°C.  
Gonococcal liquid media was prepared as described by Blake et al. (1981). Media 
was modified to increase proteose peptone from 11.25 grams per liter to 15 grams per 
liter.  
 
Purification of PorB from N. gonorrhoeae MS11∆P3 by Chromatography  
 
Buffer A: 50 mM Tris, 10 mM EDTA, 0.05% Zwittergent 3-14, and 0.02% 
sodium azide, pH 8.0 was used to wash DEAE/CM columns. Buffer A at pH 7.5 was 
used for protein absorption on the Matrex Cellufine Sulfate column.  
 Buffer B: 50 mM Tris, 10 mM EDTA, 0.05% Zwittergent 3-14, 0.02% sodium 
azide, and 0.8M NaCl, pH 8.0 or pH 7.5 was used for protein elution from the DEAE/CM 
and Matrex columns, respectively.  
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 Buffer C: 100 mM Tris, 10 mM EDTA, 0.05% Zwittergent 3-14, 0.02% sodium 
azide, and 0.2 M NaCl, pH 8.0 was used for protein separation by gel filtration 
chromatography.  
 
Cell Culture 
 
Dulbecco’s Modified Eagle Medium (DMEM, Corning Cellgro, #10-012-CV), 
supplemented with 5% fetal bovine serum (FBS), 5% ciprofloxacin, and 1%L-glutamine, 
was used to culture HEK293 cells.  
 Roswell Park Memorial Institute 1640 Media (RPMI, Corning Cellgro, #15-040-
CM), supplemented with 10% FBS, 1% Penicillin/Streptomycin, and 1% L-glutamine, 
was used to culture Bone Marrow Derived Macrophages (BM-DM).  Media was termed 
R-10. 
 
Purification of N. gonorrhoeae MS11∆P3 PorB 
 
Neisseria gonorrhoeae Strains and Growth:  
 
All bacterial strains were cultured from frozen stocks kept at -80°C. Neisseria 
gonorrhoeae strain MS11∆P3, an RMP-deficient strain, was plated onto a gonococcal 
agar plate and incubated overnight in a  37°C,5% CO2 incubator (L M Wetzler et al., 
1992)
 . 
Following overnight growth, colonies were used to inoculate 50 mL of liquid 
gonococcal media. After 6 hours, the culture was transferred into 4 flasks containing 
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50mL gonococcal media each and incubated an additional 6 hours in an Innova 4000 
Incubator shaker at 37°C. The resulting cultures were transferred to 4 Fernbach flasks, 
each containing 1.5L of media and incubated overnight with shaking (L M Wetzler et al., 
1992). Neisseria gonorrhoeae MS11 parent strain was cultured as described above.  
 The crude outer membrane proteins were prepared by extraction with zwittergent-
Ca2+ method as described by Blake and Gotschlich (Blake & Gotschlich, 1984). Briefly, 
the 6L cultures were centrifuged at 5000 rpm for 15 minutes at 25°C to pellet the 
bacteria. The pellet was washed with cold 0.9% NaCl and slowly resuspended into a 
smooth slurry in a solution containing 1.0 M sodium acetate and 0.1% 
dimercaptopropanol (BAL), as an anti-protease. The suspension was centrifuged as above 
and the supernatant was placed into a glass beaker and transferred into a water bath 
sonicator. While sonicating, 0.5M CaCl2 and 5% Zwittergent 3-14 solutions were added 
to the suspension. DNA, LOS, and cellular debris were precipitated by the addition of 
ethanol (EtOH) to a final concentration of 20% (v/v). The suspension was then removed 
from the sonicator and centrifuged at 5000 rpm for 15 minutes at 4°C. The supernatant 
was collected and precipitated in ethanol (EtOH, 80% v/v) overnight at 4°C.   
  The solution was centrifuged at 5000 rpm for 15 minutes at 4°C and the resulting 
pellet contained all outer membrane proteins, lipoproteins, and remaining LOS. 
Afterwards, the protein pellet was resuspended in 50 mM Tris, pH 8.0, 10 mM EDTA, 
5% Zwittergent, and 0.02% sodium azide solution in a water bath sonicator. The protein 
suspension was centrifuged at 10,000 rpm for 15 minutes and supernatant was collected. 
The supernatant is termed the starting material (SM).  
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Purification by Chromatography (Biochemistry) 
 
Ion Exchange Chromatography 
 Purification and proteosome formation was carried out in the manner described by 
Massari et al. (Massari et al., 2005). Two ion exchange columns were used in tandem: a 
Diethylaminoethyl (DEAE) sepharose 6B-CL (Amersham) column and Carboxymethyl 
(CM) sepharose (Amersham) column (2.5x10cm, Econo column; Bio-Rad, Hercules, CA, 
USA). Absorbance was monitored at 280nm by an Amersham Biotech ÄKTA Prime 
fraction collector. Both DEAE and CM columns were equilibrated and run with Buffer A 
at pH 8.0. The SM was applied at a flow rate of  1.8 mL/minute until the absorption 
reading returned to baseline. The flow through and wash fractions were collected. The 
columns were then eluted with Buffer A containing 0.2M NaCl. The resulting solution 
was collected. The OD reading was allowed to peak and return to baseline prior to a 
stepwise increase to 0.5M NaCl. A final 0.8M NaCl, wash was applied to remove any 
residual proteins from the resin. Samples of fraction were collected and precipitated in 
80% EtOH for subsequent analysis by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and Coomassie staining. The porin containing fraction was 
then precipitated with 80% EtOH (v/v) overnight at 4°C. The solution was centrifuged at 
5000 rpm for 15 minutes at 4°C and the pellet was resuspended in buffer containing 
50mM Tris, pH 8.0, 10mM EDTA, 5% Zwittergent 3-14, 0.02% sodium azide. 
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Gel Filtration Size Exclusion Chromatography 
The protein suspension separated by gel filtration chromatography on a Sephacryl 
S-300 column (2.6x180 cm, Amersham) using Buffer C at a flow rate of 0.3mL/minute.. 
Fractions of  10 mL were collected and analyzed by Coomassie staining of SDS-PAGE, 
as above. PorB containing fractions were combined and precipitated in 80% EtOH 
overnight at 4ºC. Precipitated proteins were centrifuged at 5000 rpm for 15 minutes at 
4°C. The resulting pellet was resuspended in 50mM Tris, pH 7.5, 10mM EDTA, 5% 
Zwittergent 3-14, 0.02% sodium azide.  
 
Affinity Chromatography 
 The protein solution was loaded on a Matrex Cellufine Sulfate resin (Millipore, 
Billerica, MA, USA) column (2.5x10 cm Econo column) in Buffer A at pH 7.5 at a flow 
rate of 5mL/min. The column was washed with Buffer A until the absorbance returned to 
baseline. The flow through and the wash were collected and then a linear gradient of 0.2-
0.5M NaCl was applied and 4 mL fractions were collected. Protein elution was monitored 
via chromatograph OD measurements. The porin containing fractions, eluted between 
0.24-0.4M, were analyzed by Coomassie stain of SDS-PAGE and precipitated in 80% 
(v/v) EtOH.   
 
Proteosome Formation 
 The pooled fractions were centrifuged at 5000 rpm for 15 minutes at 4°C and the 
pellet was resuspended in 10% D-octyl glucoside (DOG)-10mM HEPES, pH 7.2. The 
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protein suspension was dialyzed extensively against PBS containing 0.02% sodium azide 
(>5x1010 times the original sample volume over 36 hours). The dialysis process yields 
micelles containing porin in its active trimeric state (Massari et al., 2005). Proteosomes 
were stored at 4ºC to prevent quaternary structure degradation.  
 Protein concentration was determined using the Bio-Rad Protein Assay kit as per 
manufacturer’s instructions. Proteosomes were diluted 1:2 and 1:4 in a 96 well plate. 40 
µL of Bio-Rad protein assay Dye Reagent Concentrate and 150 µL of dH2O were added 
to the samples. Bovine serum albumin (BSA) was used as the standard, starting at 
2mg/mL and serially diluted. The standard was loaded and developed alongside the 
samples. The plate was read by Molecular Device’s Spectramax190 microplate reader at 
594 nm and protein concentration was extrapolated from the standard curve by linear 
regression.  
 
Phenotypic Characterization of Purified Protein  
 
SDS-PAGE and Immunoblot 
 
Neisseria gonorrhoeae strain MS11∆P3 was analyzed for the presence of outer 
membrane protein, RMP, by Western blot analysis. N. gonorrhoeae strain MS11∆P3 was 
streaked onto gonococcal agar and incubated at 37°C overnight. A small sample of the 
bacteria was lysed in dH2O and 1X SDS-loading dye (250mM TrisHCL pH 6.8, 10% 
SDS, 30% Glycerol, 5% β-mercaptoethanol, 0.02% bromophenol blue) was added. The 
sample was heat denatured for 5 minutes at 95°C. 10, 5, and 2 µL samples of the lysate 
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were analyzed on 12% SDS-PAGE run at 150 V on ice for 1.5 hours until Fisher 
BioReagents EZ-Run™ Prestained Rec Protein Ladder (BP3603-1) was well separated. 
1µg of previously purified porin from the parent N. gonorrhoeae MS11 strain and 10 µL 
of a N. meningitidis H44/76 strain cell lysates served as positive controls. 2µg Ovalbumin 
(Ova) and 10 µL cell lysates from N. meningitidis H44/76∆1∆4, lacking RMP, served as 
negative controls.  
Separated samples were transferred from the 12% SDS-PAGE to a poly-
vinylidene fluoride (PVDF, Hydrobond) membrane at 200 milliamps for 1 hour using the 
Bio-Rad tankblot system. Ponceau red, a rapid reversible protein stain, was used to 
confirm successful transfer of protein from SDS gel to membrane. The membrane was 
blocked for 1 hour at room temperature (RT) in Tris Buffered Saline Tween 20 (TBST) 
containing 5% (wt/v) non-fat milk powder (TBST-Milk) and subsequently incubated 
overnight at 4ºC with a mouse anti-RMP primary antibody, diluted 1: 2000 in TBST-
Milk. The next morning, the membrane was washed three times with TBST-Milk for 15 
minute periods. Afterwards, the membrane was incubated with an HRP-conjugated anti-
mouse secondary antibody for 2 hours at RT. Thereafter, the membrane was washed 
twice with TBST-Milk and TBST for 15 minutes each. The membrane was developed 
using GE Amersham Plus ECL kit as per manufacturer instructions. The membrane 
surface was covered with detection solution, containing solutions A and B at a 40:1 ratio, 
for 5 minutes at RT. The excess buffer and detection solutions were drained and the 
membrane was secured in plastic wrap and x-ray film cassette. Amersham Hyperfilm 
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ECL autoradiography film was placed over the wrapped blot for 30 seconds. The film 
was developed and read.   
Proteosomes were also analyzed by Western Blot with a gonococcal anti-PorB 
antibody. 0.5, 1, and 2 µg samples of the proteosomes were analyzed by 12% SDS-PAGE 
at 200V on ice for 1 hour and subsequently transferred to PVDF (Hydrobond) membrane 
at 200Amps for 1 hour as described above. The membrane was blocked with TBS-Milk 
solution for 1 hour at 25ºC. The membrane was incubated overnight at 4ºC with a rabbit 
anti-PorB antibody diluted at 1:1000 in TBST-Milk. The following day, the membrane 
was washed with TBST-Milk three times at room temperature for 20 minutes each. HRP-
conjugated donkey anti-rabbit secondary antibody, diluted 1:20,000, was applied to the 
membrane for 2 hours at RT. Afterwards, the membrane was washed twice with TBST-
Milk and TBST. The membrane was developed, as above, using GE Amersham Plus ECL 
kit.   
 Detection of the endotoxin, LOS, was carried out by silver stain (Fomsgaard et 
al., 1990). A 10 µL sample of the protein was run on a 15% SDS-PAGE alongside other 
chromatography fractions, including the Matrex starting material, the flow through, and 
purified LOS (1 µg/mL), the gel was run at 200V for 1 hour. The Bio-Rad Silver Stain 
Kit was used to perform the silver stain and all steps were carried out at room 
temperature unless otherwise specified. The SDS-PAGE was then transferred into a 
50mL glass staining dish containing 40%methanol/10%acetic acid (v/v) fixative solution 
for 30 minutes. Two additional fixing steps were performed using 10% ethanol/5% acetic 
acid for 15 minutes. Oxidizer solution was applied for 5 minutes followed by 6-8 
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deionized water washes to eliminate the Oxidizer solution. The Silver reagent was then 
applied for 20 minutes followed by one deionized water wash. Developer solution was 
added in stages until LOS positive control was strongly visible. The reaction was stopped 
with cold 5% acetic acid (v/v)(L M Wetzler et al., 1992).  
 
Immune Stimulatory Activity  
 
Cell Culture 
 
HEK Cells  
 Human embryonic kidney (HEK) 293 cells transfected to overexpress TLR2, 
TLR4, or an empty vector, as control (pcDNA HEK293 cells). The cells were grown to 
confluence in Dulbecco’s Modified Eagle Medium (DMEM) containing 5% fetal bovine 
serum (FBS), 1% L-glutamine, and 5% ciprofloxacin and incubated at 37°C, 5% CO2 as 
described by Massari et al. (2005)
. 
The cells were then plated at1x105 cells/mL and 
cultured in the above media. 
 
Bone Marrow Derived Macrophage (BM-DM) Isolation and Culture 
BM-DM isolation was carried out as previously described by MacLeod and 
Wetzler (2007). An 8-10 week old, female C57-BL6 mouse was sacrificed via CO2 
chamber and cervical spine dislocation. The fore- and hind legs were dissected and the 
bones were removed. The bone marrow was flushed from bones with pre-warmed R-10 
cell culture media using a 27 gauge needle and syringe system. The resulting solution 
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was centrifuged at 1500 rpm for 5 minutes at RT and supernatant was discarded. The 
pellet was resuspended in 1 mL Ammonium-Chloride-Potassium (ACK) lysing buffer to 
remove red blood cells. The solution was diluted using PBS, then further centrifuged at 
1500 rpm for 5 minutes. The supernatant was removed and the cells were resuspended in 
R-10 media. Cells were counted and plated at 3x106 cells per 10mL of R-10+20% L-929 
media and incubated at 37°C and 5% CO2. Media was changed out for fresh R-10+20% 
L929 on day 3. Cells were ready for stimulation on day 7.  
 
Cell Stimulation  
 
HEK Cell Stimulation  
HEK cell stimulation was carried out as previously described by Massari et al.  
(2006). HEK TLR2, HEK TLR4, and HEK pcDNA cells were plated on a  96 
well plate and incubated for 24 hours at 37°C with one of the following treatments: media 
only (negative control), PorB (10µg/mL), PorB (1µg/mL), Pam3CSK4 (200ng/mL, a 
known TLR2 ligand), Lipopolysaccharide (LPS) (200ng/mL, a known TLR4 ligand), and 
TNF-α (20ng/mL, a TLR-independent stimulator). The experiment was carried out in 
triplicate. Following the exposure period, supernatants were removed and reserved at        
-80ºC for subsequent analysis by ELISA. 
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Macrophage Stimulation 
The macrophages were plated at 1x105 cells/mL and exposed to one of 5 
treatment groups for 24 hours. Treatment groups included:  media only (negative 
control), PorB (10µg/mL), PorB (1µg/mL), Pam3CSK4 (200ng/mL, positive control), 
LPS (200ng/mL, positive control) (MacLeod & Wetzler, 2007). Stimulation was carried 
out in triplicate. Following the exposure period, supernatants were removed and reserved 
at -80°C for subsequent analysis by ELISA.  
 
Immunization 
 
 Animal use and standards of care in this experiment was approved by the 
Institutional Animal Care and Use Committee (IACUC). The vaccination study was 
modeled after a similar study performed in the Wetzler lab using rabbits (L M Wetzler et 
al., 1992). 10 female C57/BL6 mice were obtained from Jackson Laboratory at 8 weeks 
of age and used in a 7 week immunization experiment. Pre-immune plasma was collected 
by tail bleed from each mouse. Blood flow was encouraged through pre-warming of the 
mice with a heat lamp. Mice were bled from the ventral tail vein while secured in a 
restrainer. Approximately 180µL of blood were collected per mouse into EDTA-coated 
tube. Collected blood samples were centrifuged at 1400 rpm for 10 minutes at RT and 
plasma was removed and stored at -80°C for later analysis by ELISA. Subsequently, 
10µg of PorB in 100µL of PBS was delivered subcutaneously to each mouse. This 
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process was repeated at 2 week intervals to total 3 immunizations and 4 bleeds. After 7 
weeks, mice were sacrificed and a final blood draw by cardiac puncture was performed.  
 
ELISA 
 
IL-8 
The BD Human IL-8 OptEIA kit (#555244) was used as recommended by the 
manufacturer, to determine interleukin-8 (IL-8) levels derived from stimulated HEK293 
cells. An ELISA plate was coated with IL-8 capture antibody in coating buffer (1:250) 
and incubated overnight at 4°C. The plate was washed 3 times with PBS containing 
0.05% Tween-20 (PBS-Tween) washing buffer and blocked with assay diluent, 10%FBS 
in PBS, for 2 hours at RT. Serial dilutions (starting at 200 pg/mL, 1:2 up to 11 dilutions) 
of recombinant IL-8 were added together with the experimental supernatants (diluted 1:2) 
and incubated for 2 hours at RT. An additional 5 washes were performed. Detection 
antibody (1:250) and Avidin-HRP (1:250) in assay diluent were added in tandem and 
allowed to incubate for 1 hour. Finally, 7 additional washes were performed and the 
substrate, Tetramethylbenzidine (TMB, BD OptEIA #555214), was added to the plate 
and incubated for 35 minutes at room temperature in the dark. The reaction was stopped 
using 50 µL 2N H3PO4 and read by Molecular Device’s Spectramax190 microplate 
reader at 450nm. The amount of IL-8 was extrapolated from the standard curve using a 
linear regression function.  
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TNF-α 
 TNF-α produced by the BM-DMs after stimulation was detected using the 
eBioscience TNF-α ELISA Ready-Set-Go!® kit (#88-7324-88) as per manufacturer 
instructions. An ELISA plate was coated with kit-provided capture antibody diluted in 
coating buffer (1:250) overnight at 4ºC. The plate was washed 3 times with PBS-Tween 
washing buffer and blocked with assay diluent for 2 hours at room temperature. A 
reference standard curve, consisting of serial dilutions of TNF-α of known concentration 
(starting at 1000 pg/mL diluted 1:2 ten times) was added to the plate, along with the 
collected supernatant samples, diluted 1:2, for an additional 2 hour incubation at RT. An 
additional 5 washes were performed. Detection antibody (1:250) was added to the plate 
and allowed to incubate for 1 hour. The plate was washed 5 times and Avidin-HRP 
(1:250) was added and incubated for 30 minutes. Finally, 7 additional were performed 
and the substrate, TMB solution, was added to the plate which was incubated for 25 
minutes at room temperature in the dark. The reaction was stopped using 50 µL of 2N 
H2SO4 and absorbance at 450nm was read by the SpectraMax microplate reader. The 
amount of TNF-α was extrapolated from the standard curve using a linear regression 
function.  
 
PorB Specific IgG Detection 
 PorB IgG detection was carried out as described previously by the Wetzler lab (L 
M Wetzler et al., 1992). Sera from mice were analyzed for PorB specific IgG by ELISA. 
Standard wells were coated with 100µL of 10µg/mL F(ab)2 Fragment Goat Anti-Mouse 
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IgG (Affinipure, 115-006-006) in PBS. Sample wells were coated with 2µg of PorB in 
carbonate buffer, pH 9.6. The prepared plate was incubated overnight at 4°C. The 
following morning, the plate was washed 3 times with PBS-Tween. The plate was 
subsequently blocked with 5% BSA in PBS for 1 hour at room temperature. Following 
blocking, serial dilutions of mouse IgG standard (Sigma, #15381) and individual mouse 
sera were incubated at 4°C overnight. Afterwards, the plate was washed, then incubated 
for an additional 2 hours with Sigma anti-mouse IgG (γ chain specific) alkaline 
phosphatase (A3438 SLBC9630V, diluted 1:10,000). The plate was subsequently washed 
and 1 Step PNPP® substrate solution (ThermoScientific, 37621) was added and the plate 
was incubated for 30 minutes at room temperature. The absorbance was measured at 
405nm by Molecular Device’s Spectramax 190 microplate reader. The amount of porin-
specific IgG was extrapolated from the standard curve using a linear regression function. 
  
 Purification of N. gonorrhoeae
 
Ion Exchange Chromatography
 
 Initial purification by ion exchange 
columns (pH 8.0) yielded high recovery of PorB in the flow through
A,B). The DEAE Flow T
Flow Through and the second termed Flow T
low and high molecular weight contaminants were found in higher concentrations in the 
subsequent 0.2M NaCl wash. 
50mM Tris, pH 8.0, 10mM EDTA, 5% Zwittergent 
processing. 
A)  
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RESULTS 
 MS11∆P3 PorB by Chromatography  
 
chromatography on the DEAE and CM 
 fraction
hrough was collected over two days, the first fraction termed 
hrough remainder (Fig. 1B). 
The FT was collected, precipitated, and resuspended in 
3-14, 0.02% sodium 
 (FT) (Fig. 1 
Comparatively, 
azide for further 
 
B)   
Fig. 1.Purification by Ion Exchange Chromatography 
DEAE/CM column, absorbance read at 280nm.  B) 
analysis of chromatography fractions, from left to
NaCl Wash, 0.5M NaCl Wash, and 100% Buffer B wash
the boxed area. FT was collected for further purification  
 
 
Separation by Size: Gel Filtration
 
 Two runs of separation by Gel Filtration on Sephacryl 300 column were 
performed in parallel due to volume of protein solution derived from DEAE/CM 
columns. GF columns were run in parallel, one 
fraction collector and the other 
absorbance reader. The columns were set to the parameters indicated in methods and run 
in parallel. This chromatography separated PorB from much 
contaminant proteins with the exceptio
~60 KD  proteins. Fractions 25
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A) Chromatograph of 
12% SDS-PAGE and Coomassie 
 right, SM, FT, FT remainder, 0.2 M 
. PorB (~34KD)
 
 
using an Amersham ÄKTA prime 
manually with a peristaltic pump not equipped with an 
the majority of the
n of LOS traces and two persistent ~75KD and 
-34 were pooled from the automated column (Fig. 2A, B). 
 
 is indicated by 
 
Fractions 42-49 were pooled from the manual column (Fig. 2C.). Pools were combined 
and precipitated with 80% (v/v) EtOH
A) 
B) 
 
26 
 
.  
 
 
C) 
 
Fig. 2. Gel Filtration: Separation by Size Exclusion 
read at 280nm absorbance. B) 
PAGE, matched to above chromatograph. 
indicated by boxed area, fractions pooled. 
of 12% SDS-PAGE in fractions collected fr
49, indicated by boxed area. 
   
 
Affinity Chromatography
 
The protein precipitate was 
5% Zwittergent 3-14, 0.02% sodium azide and loaded onto a Matrex Cellufine Sulfate 
resin column. This resin does not bind endotoxin but will bind PorB at pH 7.5. Thus,
LOS and other lipoproteins are expected to be removed in the 
Through fraction and the wash were collected together and the proteins were eluted by 
applying a 0.2-0.5M NaCl gradient 
concentration between 0.24
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A) Gel Filtration Chromatograph, 
Visualization of PorB by Coomassie stain of 
PorB was determined to be in fractions 25
C) Visualization of PorB by Coomassie stain 
om the manual machine. Pooled fractions 42
 
 
resuspended in 50mM Tris, pH 7.5, 10mM EDTA, 
Flow Through. The Flow 
and collecting 4 mL fractions. PorB was eluted 
-0.4M NaCl. As before, samples were collected and analyzed 
 
 
12%SDS-
-34, 
-
 
at a 
by SDS-PAGE and Coomassie staining. 
fractions, fractions 10-24 were pooled and precipitated (Fig. 3
A) 
B)
Fig. 3. Matrex Cellufine Sulfate 
Chromatograph, Pooled fractions indicated by bar. Applied 0.2
indicated by sloped line on the 
stained by Coomassie to identify fractions containing PorB
fractions 10-25, indicated by boxed area, pooled fractions. 
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Following Coomassie assisted analysis of these 
A, B).   
Chromatography : used for removal of LOS A) 
-0.5M NaCl gradient 
chromatograph. B) Samples analyzed by12% SDS
. PorB was determined to be in 
  
       
         
-PAGE, 
As shown in figure 3B, 
the precipitated fractions were
Zwittergent 3-14, 0.02% sodium azide and further
chromatography in which smaller 4 mL fractions were collected, t
proteins by size. Resulting fractions were analyzed by 12% SDS
(Fig. 4 A,B), showing a significantly improved protein preparation, although 
quantities of ~75KD and ~60 KD
Nonetheless, PorB was determined to be the most significant immunogenic agent present 
and fractions were pooled for further processing into proteosomes. 
 
A)
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a high level of contaminant proteins was detected
 resuspended in 50mM Tris, pH 8.0, 10mM EDTA, 5% 
 separated by an additional
o better separate the 
-PAGE and 
 MW proteins and three lower MW proteins
 
. As a result, 
 gel filtration 
Coomassie 
 low 
 persist. 
 
B)
Fig. 4. Further Purification by Size Exclusion
contaminants A) Chromatograph
PAGE  stained by Coomassie. Pooled fractions 37
 
 
Phenotypic Characterization of Purified Protein
 
As contamination of purified PorB by RMP w
formation, it was imperative to analyze the strain for presence of RMP. Presence of RMP 
in the strain would preclude the ability to proceed as RMP and PorB cannot be separated 
through subsequent protein purification due to thei
gonorrhoeae MS11∆P3 lysates were obtained as stated in Methods and probed alongside 
a known RMP knock-out 
meningitidis H44/76 parent strain and 
an unassociated protein, was used to confirm specificity of antibody binding. Western 
Blot confirms lack of RMP in 
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 for additional separation of PorB
 of  B)Fractions were analyzed for PorB by
-46, indicated by boxed area. 
 
ould inhibit robust antibody 
r close molecular association. 
N. meningitidis H44/76∆1∆4, and known RMP containing
N. gonorrhoeae MS11 PorB. Ovalbumin (OVA), 
N. gonorrhoeae MS11∆P3 (Fig. 5).  
  
 from 
12% SDS-
 
N. 
 N. 
 
 Fig. 5. Determination
RMP in MS11∆P3 lysate was determined by Western Blot analysis. 
gonorrhoeae MS11
PorB purification containing RMP
meningitidis H44/
meningitidis H44/76 parent strain lysate, 
MS11∆P3 does have not contain RMP as detectable by Western Blot. 
 
 
The purified protein sample was analyzed to ensure true isola
PorB was formed into proteosomes free of detergent in process stated in Methods (Fig. 
6A). Final concentration of PorB was 2.6µg/µL as determined by the 
Assay kit. The proteosomes were then probed with anti
purification of the proper protein species. Western Blot 
of PorB. Additional bands seen at lower molecular weights are believed to be degradation 
products of PorB (Fig. 6B). 
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 N. gonorrhoeae MS11∆P3 RMP Status. 
∆P3 lysate (10,6, and 2 µL).  Lane 4: N. gonorrhoeae 
, 1µg. Lane 5: OVA protein (2µg). Lane 6: 
76∆1∆4, lysate 10 µL, known RMP- strain. Lane 7: 
10µL. Conclusion: N. gonorrhoeae 
tion of the porin. 
Bio
-PorB antibody to confirm 
analysis demonstrated presence 
 
 
Absence of 
Lanes 1-3: N. 
MS11 
N. 
N. 
 
-Rad Protein 
A)      
B)
Fig. 6. N. gonorrhoeae
proteosome samples (1 µg and 3 µg) were analyzed by
with Coomassie. PorB 
proteosomes using anti
 
 
 Sample purity was further assessed by silver stain to rule 
contaminating LOS. Following purification on the Matrex Cellufine Sulfate resin column, 
a sample of fraction 14 was analyzed against pre
flow through, and LOS by silver stain. Silver stain analysis showed no detectable traces 
of LOS in the PorB proteosome preparation (Fig. 
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 MS11∆P3 PorB Proteosome Preparation 
12% SDS-
indicated by boxed area. B)  Western Blot 
-PorB antibody 
out the presence of
-Matrex starting material, the Matrex 
7).  
A) PorB 
PAGE stained 
analysis of PorB 
 
Fig. 7. Silver Stain to Detect LOS  
(SM), 2) Matrex Flow Through (FT), 3) Matrex Fraction 14 (f. 14) 4) LOS 
15% SDS-PAGE and silver stained. The presence of LOS can be seen in the SM and 
LOS positive control and is absent in f. 14. 
 
Immune Stimulatory Activity
 
PorB Stimulates HEK Cell 
 
Stimulation studies of 
or TLR4 were performed to determine if the gonococcal PorB we have isolated has a 
similar immune-stimulatory ability as meningococcal PorB. 
(10µg/mL) resulted in a 5.7 fold increase in IL
 
33 
 
From left to right 1) Matrex Starting Material 
 
 
 
control HEK293 cells and HEK293 cells expressing TLR2 
Stimulation by PorB 
-8 production in TLR2 cells as compared 
 
analyzed by 
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to the media only control. Conversely, PorB did not induce IL-8 production in the TLR4 
HEK cells(Fig. 8). Similar fold changes in IL-8 production were found in the 1µg/mL 
PorB treatment group which suggests that the ability of PorB to induce IL-8 production in 
these cells might have been close to saturation in the contexts of this assay. Experimental 
controls behaved as expected with one notable exception wherein the ELISA obtained 
negative values for the LPS stimulation of pcDNA cells (data not shown). This is likely 
due to the ELISA reader program subtracting the designated “blanked” wells OD value 
from all sample readings and indicates that that optical density of LPS stimulation was 
marginally less than that of the blank itself. As LPS is not expected to stimulate pcDNA 
cells, this result is in line with expectations.  
 
Fig. 8. Hek293 Stimulation Study: PorB as a TLR2 Ligand Comparison of PorB 
stimulation of HEK293 cells expressing TLR2 and TLR4. PorB is seen to stimulate 
TLR2 HEK cells at both 10 and 1 µg/mL while failing to stimulate TLR4 expressing 
cells. Pam3CSK4, TNF-α, and LPS controls behaved as expected.  
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PorB Stimulates Murine Antigen-Presenting Cells: Macrophages  
 
 Stimulation of bone marrow derived macrophages (BMDM) was determined by 
measurement of TNF-α production through ELISA using cellular supernatant harvested 
24 hours after exposure to PorB with Pam3CSK4 and LPS as positive controls. Treatment 
with 10µg/mL of PorB resulted in a 44.5 fold increase in TNF-α production as compared 
to media only control. Treatment with 1µg/mL of PorB resulted in a 25.8 fold increase in 
TNF-α production. Experimental controls behaved as expected, stimulation by 
Pam3CSK4 yielded a 40.5 fold increase while stimulation by LPS resulted in a 22 fold 
increase of TNF-α as compared to the media control (Fig. 9.).  
 
Fig. 9. PorB Stimulates Macrophages, a class of Antigen Presenting Cells 
(APC)Stimulation of Bone Marrow Derived Macrophages by PorB (10µg/mL, 1µg/mL), 
Pam3CSK4, LPS as measured by TNF-α production.  
 
0
200
400
600
800
1000
- 10µg 1µg 200ng 200ng
Medium PorB PorB Pam3 LPS
TN
F-
α
(pg
/m
L)
 36 
 
Immunogenicity of PorB Vaccine  
 
 Sera obtained from the mice at each time point was analyzed by ELISA as 
described in Methods. Pre-immune blood was consistently low in PorB specific IgG. 
Following the first immunization, mice showed negligible increases in antibody counts. 
A minimum of two-fold increase was observed in sera following the second 
immunization of mice 3, 4, 6, 8, 9, 10. The most significant increases were observed after 
the third immunization. Immunization in mice 1,2, and 5 were unsuccessful (Fig. 10).  
Mice 4, 6, 7, 9, and 10 experienced between a 7 and 9 fold increase in PorB specific 
antibody over the course of the study. Mouse 8 represents the most promising 
immunization with a 50 fold increase. However, these values fall well below the values 
found by the Wetzler lab in their 1992 evaluation of immunogenicity of PorB 
proteosomes (L M Wetzler et al., 1992). 
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Fig. 10: PorB Specific IgG Detected in Sera over Immunization Course: Sera from 10 
mice as measured for anti-PorB IgG by ELISA. Mice 1, 2, and 5 represent unsuccessful 
immunizations. Mice 3,4,6,7,9, and 10 show moderate 7-11 fold increases in PorB 
specific serum IgG. Serum IgG measured from mouse 8 reflects a 50 fold increase. 
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DISCUSSION 
 
 The emergence of ceftriaxone-resistant Neisseria gonorrhoeae represents a 
significant threat to global reproductive health and necessitates the development of an 
effective, cross-protective anti-gonococcal vaccine. In an attempt to address this need, 
our project focused on purification and characterization of the gonococcal vaccine 
candidate, PorB. As previously discussed, gonococcal PorB is the major outer membrane 
protein expressed on the cell surface, has low antigenic variability and is believed to 
induce robust antibody response through the TLR2/MyD88 signaling. Antibodies to PorB 
have bactericidal activity.  
 PorB was purified from Neisseria gonorrhoeae strain MS11∆P3 as previously 
described (Massari et al., 2005). Proteins were extracted and subjected to column 
chromatography, after which porin was formed into protein containing micelles to 
preserve quaternary structural integrity. The innovative addition of the Matrex Cellufine 
resin by Massari et al. in 2005 allowed for elimination of LOS and remaining lipoprotein 
contamination from the final preparation. Unfortunately, in this particular purification of 
GC PorB, a small amount of two high molecular weight components remained present 
despite additional size separation by gel filtration chromatography (Fig. 4B). Based on 
initial analysis by Coomassie staining, it was believed that these proteins may correspond 
to high molecular weight forms of PorB. However, an anti-PorB antibody did not bind to 
these proteins as shown in subsequent Western Blot analysis (Fig. 6). It is possible that 
the observed high molecular weight contaminant traces derive from non-optimal 
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separation by size exclusion chromatography as the starting material loaded to the 
columns may have exceeded the gel filtration column capacity. Nonetheless, PorB was 
the most immunologically significant molecule in the preparation and further studies 
were carried out. In the future, potential, optimization of gonococcal PorB purification 
could be undertaken by adjustment of Matrex Cellufine Sulfate column buffer pH.  
 Stimulation of HEK293 cells with the PorB resulted in a robust IL-8 response in 
TLR 2 containing cells with no IL-8 production in TLR 4 and pcDNA containing cells. 
These results indicate signaling through the TLR 2 pathway, corresponding with known 
behavior of the N. meningitidis PorB. The consistency in elicited response between the 
present preparation of gonococcal porin with past preparations of meningococcal porin 
serves as additional validation of the intact trimeric state.  
 Exposure of murine BM-DMs to the PorB resulted in TNF-α production that was 
comparable to the known immunostimulatory agents, Pam3CSK and LPS , supporting the 
hypothesis that PorB interacts with and stimulates antigen presenting cells.  
 Immunization of wild type C57/BL6 mice with PorB in the absence of an 
exogenous adjuvant resulted in induction of PorB specific antibody as previously shown 
in the rabbit model(L M Wetzler et al., 1988, 1992). However, antibody titers from the 
mouse were approximately 20-fold less than titers from the rabbit. The discrepancy in 
humoral responses may be attributable to a number of factors. The use of the Bio-Rad 
protein assay kit instead of the Pierce® BCA kit for proteosome concentration 
determination may have resulted in over-estimation of porin content and lowered 
immunogenic load injected into the mice. However, the strong IL-8 and TNF-α responses 
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from the stimulated HEK and macrophage cells, respectively, are inconsistent with such 
overestimation. Alternatively, the observed low antibody detection may be attributable to 
non-optimal coating of the ELISA plate wells with PorB. To verify proper coating, an 
anti-PorB sera from previous immunization experiments, such as that used for the 
Western Blot analysis, will be used as a positive control. Additionally, wells will be 
coated with either PorB in zwittergent, as before, or using the PorB proteasome 
preparation comparison. There is also the possibility that PorB does not self-adjuvate in 
the mouse model as effectively as in the rabbit model. However, many studies have 
shown the strong immunopotentiating capabilities of PorB in both mice and rabbits when 
delivered in tandem with separate antigen (Platt et al., 2013; L M Wetzler et al., 1988). 
Additional examination of the collected sera is underway to verify this data, with the 
addition of a known anti-PorB to serve as a positive control.  
 Results from these experiments suggest that PorB is a powerful immunostimulator 
with mild to moderate antigenicity within the mouse. In collaboration with the Gray-
Owen lab and Novartis Pharmaceuticals, the Wetzler lab is investigating GC PorB, GC 
outer membrane vesicles (OMV), the combination of OMV with PorB, and Novartis 
supplied molecules as potential vaccine candidates in the Gray-Owen newly developed 
transgenic mouse. Others have identified Tf receptors, transferrin binding protein A 
(TbpA), transferrin binding protein B (TbpB), and the conserved 2C7 LOS epitope as 
potential antigenic candidates (Jerse et al., 2014). Antibodies against the 2C7 LOS 
epitope are highly bactericidal and promote opsonophagocytic killing of GC (Gulati et 
al., 1996). The Sikora group has applied isobaric tagging and liquid chromatography 
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towards proteomic analysis of 4 strains of GC, MS11, FA1090, F62, and 1291, and have 
identified 22 shared but differently abundant proteins between the strains that may be 
exploited for vaccine or treatment development (Zielke et al., 2014). 
 Further studies are required to clarify the role and efficacy of PorB as an 
immunogenic and immunostimulatory agent. Stimulation of dendritic cells, B cells, T 
cells, and macrophages derived from wild type C57/BL6, C57/BL6 TLR 2 knock out, and 
C57/BL6 MyD88 mice would complement the previous macrophage stimulation 
experiment. Further, the mouse anti-PorB IgG collected from the immunization study can 
be assayed for binding affinity to N. gonorrhoeae MS11 PorB, as well as other strains to 
see if there is the potential for serovar cross-reactivity. An additional immunization 
course with the PorB preparation could be performed followed by challenge with N. 
gonorrhoeae strain MS11 in the transgenic mice to determine if vaccination with purified 
and intact PorB confers protection. Additional mouse immunization studies should be 
considered wherein efficacy of various routes of immunization is tested. A previous study 
has shown that intravenous and intraperitoneal injections of PorB formed into 
proteosomes elicits a strong IgG response (Jiskoot et al., 1986). However, it is important 
to note that this study focuses on overall IgG concentrations in sera, not PorB specific 
IgG. Finally, it may be of interest to subject mice and rabbits to parallel immunization 
protocols to determine if there is a different in PorB antigenic activity between these two 
animal models. 
 With the rise of multidrug resistant strains of Neisseria gonorrhoeae, the 
development of an effective, cross-protective vaccine has become increasingly important. 
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Unfortunately, current animal models lack the human proteins necessary for GC 
adhesion, invasion, and colonization of the host organism. As a result, conclusions drawn 
from these models, although extremely important, may not be reflective of GC infections 
in humans. The development of humanized mice by the Gray-Owen laboratory may 
prove to be a powerful tool for unraveling the correlates of immunity, the dearth of which 
has stymied efforts in vaccine development. However, in the absence of such an animal 
model, investigations into potential vaccinogens are necessary. Due to promising results 
in the literature, attention has been turned to the neisserial major outer membrane protein, 
PorB. Making up 60% of the outer membrane contents, PorB has been a protein of 
interest for many years due to its relatively low antigenic variability, and its ability to 
stimulate B cells and dendritic cells to proliferate and mature in a TLR2/MyD88 
mediated fashion. This study confirms the immune-stimulatory function of PorB in both 
HEK cells and macrophages. However, low anti-PorB titers obtained from immunized 
mice sera indicate lower than expected antigenicity. Additional studies shall be 
undertaken to further characterize PorB as an adjuvant and an antigen. PorB is one of 
many potential vaccine candidates being assessed and the many potential vaccinogens in 
combination with developing technologies are a cause for optimism.   
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